Rizwan Bashirullah

Rizwan received his Master’s and Ph.D. degrees in Electrical and Computer Engineering from North Carolina State University. After graduating in 2004 he joined the Department of Electrical and Computer Engineering at the University of Florida where he held a tenured Associate Professorship. As a faculty he led a research group developing low power mixed-signal integrated circuits for brain-computer interfaces, neural prosthesis, and wireless biomedical microsystems. During his tenure he also worked in various roles including Research Scientist at Nvidia Research, as a Visiting Professor at KU Leuven and IMEC, Belgium, and as Chief Science Officer in a biomedical start-up, now eTectRX, where he developed in-vivo signaling technologies for medication compliance monitoring.

In 2016 Rizwan joined Galvani Bioelectronics, a joint venture between two global healthcare companies, GlaxoSmithKline (GSK) and Verily Life Sciences (formerly Google Life Sciences), a subsidiary of Alphabet Inc. At Galvani Bioelectronics Rizwan led a R&D portfolio to develop technologies for precision neuromodulation to treat chronic diseases by partnering with Verily Life Sciences, academic institutions worldwide, early-stage startups and national and global funding agencies. Since 2018 he has been Product Development Director of Neuromodulation Devices developing Galvani’s first-generation FDA-approved precision neuromodulation system for first-in-human clinical trials.

Surround yourself with the best people, put yourself out there, work hard, be kind, enjoy the process.